An Open-Label Roll-Over Study To Evaluate The Long-Term Safety And Efficacy Of DCR-PHXC Solution For Injection (Subcutaneous Use) In Patients With Primary Hyperoxaluria

Overview

About this study

The purpose of this study is to evaluate the long-term effectiveness and safety of DCR-PHXC in children and adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2) that have completed a previous DCR-PHXC clinical trial.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients that have successfully completed a previous study with DCR-PHXC.
  • Estimated GFR at screening ≥ 30 mL/min normalized to 1.73 m^2 BSA.

Exclusion Criteria:

  • Renal or hepatic transplantation (prior or planned within the study period).
  • Currently on dialysis or anticipated requirement for dialysis during the study period.
  • Documented evidence of clinical manifestations of systemic oxalosis.
  • Liver function test (LFT) abnormalities:  alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >1.5 times upper limit of normal (ULN) for age and gender.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

John Lieske, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

More information

Publications

Publications are currently not available
.
CLS-20474394

Mayo Clinic Footer